Bennouna J, et al. - For patients with progression of metastatic colorectal cancer after bevacizumab plus chemotherapy, researchers assessed the progression-free survival (PFS) rate at 4 months with chemotherapy plus bevacizumab vs cetuximab. From December 14, 2010 to May 5, 2015, investigators performed a prospective, open-label, multicenter, randomized phase 2 trial which involved 132 patients with disease progression after bevacizumab plus fluorouracil with irinotecan or oxaliplatin in patients with wild-type KRAS exon 2 metastatic colorectal cancer. According to the results of the PRODIGE18 (Partenariat de Recherche en Oncologie DIGEstive) study, after a first progression of metastatic colorectal cancer with bevacizumab plus chemotherapy, continuation of bevacizumab plus a switch of chemotherapy might be the best option.